At a glance
ClinicalIndex Comparison RecordPhase 3Active· 345 enrolled
Drug / intervention
AMG 510 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
In Brief
A Phase 3 clinical trial evaluating AMG 510 and Docetaxel for KRAS p, G12c Mutated /Advanced Metastatic NSCLC. Active but no longer recruiting, targeting 345 participants across 274 sites in 23 countries.
Detailed Summary
A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, Netherlands, Poland, Portugal, Russia, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3ActiveOverdue
202120222023202420252026
First PostedMar 2020
Enrollment StartJun 2020
Primary CompletionAug 2022
Study CompletionJun 2026
TodayJul 2026
First PostedMar 11, 2020
Enrollment StartJun 4, 2020
Primary CompletionAug 2, 2022
Study CompletionJun 24, 2026
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 6.3 years ago
Interventions
AMG 510drug
21 day cycles
Docetaxeldrug
21 day cycles